An antimycobacterial pleuromutilin analogue effective against dormant bacilli.

An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
复制标题

DOI:
10.1016/j.bmc.2018.07.034
复制
发表时间:
2018-09-15
影响因子:
3.5
通讯作者:
Kurosu M
Kurosu M
中科院分区:
医学3区
文献类型:
--
作者:
Lemieux MR;Siricilla S;Mitachi K;Eslamimehr S;Wang Y;Yang D;Pressly JD;Kong Y;Park F;Franzblau SG;Kurosu M

文献摘要

参考文献

被引文献

相似文献

截短侧耳素是一种很有前途的药效团,可用于设计新的革兰氏阳性菌抗菌药物。然而,关于抑制结核分枝杆菌(Mtb)生长的截短侧耳素类似物的开发的研究有限。在我们的截短侧耳素衍生物文库的筛选中,UT-800(1)被鉴定为杀死复制型和非复制型Mtb,MIC值分别为0.83和1.20 μg/mL。UT-800在2xMIC浓度下也比利福平更快地杀死细胞内Mtb。药代动力学研究表明,1具有口服生物利用度,平均F值为27.6%。截短侧耳素有可能被开发成口服抗结核药物。
Pleuromutilin is a promising pharmacophore to design new antibacterial agents for Gram-positive bacteria. However, there are limited studies on the development of pleuromutilin analogues that inhibit growth of Mycobacterium tuberculosis (Mtb). In screening of our library of pleuromutilin derivatives, UT-800 (1) was identified to kill replicating- and non-replicating Mtb with the MIC values of 0.83 and 1.20 μg/mL, respectively. UT-800 also kills intracellular Mtb faster than rifampicin at 2xMIC concentrations. Pharmacokinetic studies indicate that 1 has an oral bioavailability with an average F-value of 27.6%. Pleuromutilin may have the potential to be developed into an orally administered anti-TB drug.
DOI: 10.1128/aac.00358-13
发表时间: 2013-09-01
影响因子: 4.9
作者:
Paukner, Susanne;Sader, Helio S.;Jones, Ronald N.
通讯作者: Jones, Ronald N.
DOI: 10.1038/ja.2014.133
发表时间: 2015-04
期刊: The Journal of antibiotics
影响因子: --
作者:
通讯作者: --
DOI: 10.1073/pnas.1000643107
发表时间: 2010-07-06
影响因子: 11.1
作者:
Kong, Ying;Yao, Hequan;Cirillo, Jeffrey D.
通讯作者: Cirillo, Jeffrey D.
DOI: 10.1021/jm8000136
发表时间: 2008-04-10
影响因子: 7.3
作者:
Hirokawa, Yoshimi;Kinoshita, Hironori;Kato, Shiro
通讯作者: Kato, Shiro
DOI: 10.1016/0006-291x(91)91647-u
发表时间: 1991-03-29
影响因子: 3.1
作者:
ARTURSSON, P;KARLSSON, J
通讯作者: KARLSSON, J